The utility of Insulin Like Growth Factor Binding Proteins (IGFBPs-1, 2, 3) with genes expression in resistance to Imatinib and Nilotinib in chronic myeloid leukemia: a pilot study from Delta Egypt
African Health Sciences · 2024
DOI: 10.4314/ahs.v24i3.26 ↗Kurz gefasst
Fachartikel in der Zeitschrift African Health Sciences, 2024. Verfasst von Nadia El Menshawy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Pyrimidines, Drug Resistance, Neoplasm. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Resistance to tyrosine kinase inhibitors (TKIs) is an obstacle facing CML patients in spite of the high cure rate. In this context, a study association between IGFBP (1, 2, 3) genes expression and their proteins in CML with the response to TKI has been implicated. Patients and methods: 115 newly diagnosed CML in chronic phase (CP) followed up over 12 months under TKI. 116 apparently healthy individuals were used as a control. RT-qPCR amplification was used for detecting IGFBPs genes expression, and ELISA technique was used for measuring serum IGFBPs.
Results
IGFBP-1 and IGFBP-3 genes expression, as well as their serum levels, were significantly higher in CML patients, whereas IGFBP-2 gene expression was not. Interestingly, IGFBP-1 gene expression and IGFBP-1 serum levels were significantly higher in resistant patients compared to responder patients. However, the expression of IGFBP-2, 3 genes and their serum were insignificant.
Conclusion
IGFBP-1 gene expression and its serum were significantly correlated with resistance. It is currently recommended that IGF-receptor inhibitors be developed and utilized. We are hoping to optimize the cure rate for CML treated with TKIs. Keywords: IGFBP-1-3; Gene expression; CML; Imatinib; Nilotinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- Clinical hematology unit, oncology center, Faculty of Medicine, Mansoura university, Egypt.
- Clinical Hematology, Internal Medicine department, Faculty of Medicine, Port Said University, Port Said.
- Medical oncology unit, Oncology Center, Faculty of Medicine, Mansoura university, Mansoura, Egypt.
Zitieren
APA
El Menshawy, N., El-Ghonemy, M. S., El-Ashwah, S., Elkerdawy, H., Abbas, R., Abdelhakiem, M., Saif, M., & El-Sebaie, A. (2024). The utility of Insulin Like Growth Factor Binding Proteins (IGFBPs-1, 2, 3) with genes expression in resistance to Imatinib and Nilotinib in chronic myeloid leukemia: a pilot study from Delta Egypt. African Health Sciences. https://doi.org/10.4314/ahs.v24i3.26
Vancouver
El Menshawy N, El-Ghonemy MS, El-Ashwah S, Elkerdawy H, Abbas R, Abdelhakiem M, et al. The utility of Insulin Like Growth Factor Binding Proteins (IGFBPs-1, 2, 3) with genes expression in resistance to Imatinib and Nilotinib in chronic myeloid leukemia: a pilot study from Delta Egypt. African Health Sciences. 2024. doi:10.4314/ahs.v24i3.26
BibTeX
@article{ElMenshawy2024,
author = {El Menshawy, Nadia and El-Ghonemy, Mohamed Sabry and El-Ashwah, Shaimaa and Elkerdawy, Heidi and Abbas, Ramy and Abdelhakiem, Mostafa and Saif, Maha and El-Sebaie, Ahmed},
title = {The utility of Insulin Like Growth Factor Binding Proteins (IGFBPs-1, 2, 3) with genes expression in resistance to Imatinib and Nilotinib in chronic myeloid leukemia: a pilot study from Delta Egypt},
journal = {African Health Sciences},
year = {2024},
doi = {10.4314/ahs.v24i3.26}
}
EUVIMED